Disease Has Never Been Just Disease for Native Americans
By Jeffrey Ostler,
The Atlantic
| 04. 29. 2020
Native communities’ vulnerability to epidemics is not a historical accident, but a direct result of oppressive policies and ongoing colonialism.
As the death toll from COVID-19 mounts, people of color are clearly at greater risk than others. Among the most vulnerable are Native Americans. To understand how dire the COVID-19 situation is becoming for these communities, consider the situation unfolding for the Navajo Nation, a people with homelands in Arizona, New Mexico, and Utah. As of April 23, 1,360 infections and 52 deaths had been reported among the Navajo Reservation’s 170,000 people, a mortality rate of 30 per 100,000. Only six states have a higher per capita toll.
The spread of COVID-19 is reminiscent of previous disease outbreaks that have ravaged Native American communities. Many of those outbreaks resulted in catastrophic loss of life, far greater than even the worst-case scenarios for COVID-19. Even the 1918–19 flu pandemic, in which an estimated 650,000 Americans died (0.6 percent of the 1920 population of 106 million), pales in comparison to the losses Native Americans have suffered from disease.
Read: How the pandemic will end
Until recently, histories of disease and Native Americans have emphasized “virgin-soil epidemics.” According to this theory...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
